Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Kirkpatrick

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, et al.
Molecular Cancer Therapeutics|March 4, 2010
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitorEmmanuelle J Meuillet, Song Zuohe, Robert Lemos, et al.
Cancer Research|May 2, 2019
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cancer Research|October 17, 2019
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Experimental Cell Research|November 20, 2021
PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancerHei-Cheul Jeung, Roisin Puentes, Alexander Aleshin, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, et al.
Molecular Cancer Therapeutics|March 4, 2010
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitorEmmanuelle J Meuillet, Song Zuohe, Robert Lemos, et al.
Cancer Research|May 2, 2019
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cancer Research|October 17, 2019
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Experimental Cell Research|November 20, 2021
PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancerHei-Cheul Jeung, Roisin Puentes, Alexander Aleshin, et al.
Pageof 4